Literature DB >> 12099927

Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients.

Dj Miljkovic1, J Drulovic, V Trajkovic, S Mesaros, I Dujmovic, D Maksimovic, T Samardzic, N Stojsavljevic, Z Levic, M Mostarica Stojkovic.   

Abstract

Interleukin-6 (IL-6) and nitric oxide (NO) are implicated in the pathology of multiple sclerosis (MS). We have investigated the levels of these mediators in the cerebrospinal fluid (CSF) from 50 patients with MS and 23 control subjects. Mean CSF IL-6 level was higher in the total MS group in comparison with controls, but not significantly, whilst the difference between patients with stable MS and controls reached the level of statistical significance. Mean CSF nitrite/nitrate level was significantly higher in the total MS group compared with the control group, as well as in active MS patients versus controls. There was significant difference neither in the mean CSF IL-6 nor in nitrite/nitrate levels between active and stable MS patients. Interestingly, we observed a significant negative correlation between IL-6 and nitrite/nitrate levels in the CSF in the total MS group. Such a trend existed in both subgroups with active and stable MS, but without reaching the level of statistical significance. Our data further support the involvement of IL-6 and NO in ongoing pathological processes in MS, suggesting their potential interplay within the central nervous system in this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12099927     DOI: 10.1046/j.1468-1331.2002.00437.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

1.  IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis.

Authors:  Adam I Kaplin; Deepa M Deshpande; Erick Scott; Chitra Krishnan; Jessica S Carmen; Irina Shats; Tara Martinez; Jennifer Drummond; Sonny Dike; Mikhail Pletnikov; Sanjay C Keswani; Timothy H Moran; Carlos A Pardo; Peter A Calabresi; Douglas A Kerr
Journal:  J Clin Invest       Date:  2005-09-22       Impact factor: 14.808

Review 2.  Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Authors:  Sara J Ireland; Nancy L Monson; Laurie S Davis
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

3.  In vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: implications for MS pathogenesis.

Authors:  Caterina Serra; Giuseppe Mameli; Giannina Arru; Stefano Sotgiu; Giulio Rosati; Antonina Dolei
Journal:  J Neurovirol       Date:  2003-12       Impact factor: 2.643

Review 4.  Neuroendocrine immunoregulation in multiple sclerosis.

Authors:  Nathalie Deckx; Wai-Ping Lee; Zwi N Berneman; Nathalie Cools
Journal:  Clin Dev Immunol       Date:  2013-12-08

Review 5.  An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).

Authors:  Christopher Bolton
Journal:  Immun Ageing       Date:  2021-04-14       Impact factor: 6.400

6.  Cerebrospinal fluid level of Nogo receptor 1 antagonist lateral olfactory tract usher substance (LOTUS) correlates inversely with the extent of neuroinflammation.

Authors:  Keita Takahashi; Hideyuki Takeuchi; Yuji Kurihara; Hiroshi Doi; Misako Kunii; Kenichi Tanaka; Haruko Nakamura; Ryoko Fukai; Atsuko Tomita-Katsumoto; Mikiko Tada; Yuichi Higashiyama; Hideto Joki; Shigeru Koyano; Kohtaro Takei; Fumiaki Tanaka
Journal:  J Neuroinflammation       Date:  2018-02-17       Impact factor: 8.322

Review 7.  Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-Analysis.

Authors:  Moritz Förster; Christopher Nelke; Saskia Räuber; Hans Lassmann; Tobias Ruck; Maria Pia Sormani; Alessio Signori; Hans-Peter Hartung; Patrick Küry; Sven G Meuth; David Kremer
Journal:  Biomedicines       Date:  2021-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.